Adial Pharmaceuticals (ADIL) Restructuring Costs (2022 - 2023)
Adial Pharmaceuticals (ADIL) posted Restructuring Costs of $15895.0 for Q4 2023, down 96.06% sequentially from $403530.0 in Q3 2023, and down 57.49% YoY from $37390.0 in Q4 2022.
Adial Pharmaceuticals (ADIL) Restructuring Costs (2022 - 2023) Analysis & Trends
Adial Pharmaceuticals has reported Restructuring Costs for 2 years, with the latest figure at $15895.0 in Q4 2023.
- Quarterly Restructuring Costs fell 57.49% year-over-year to $15895.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $874856.0 (changed N/A YoY) and the FY2023 annual result came in at $471326.0, up 104.07% from the prior year.
- Restructuring Costs slipped to $15895.0 in Q4 2023 per ADIL's latest filing, from $403530.0 in the prior quarter.
- Over five years, Restructuring Costs peaked at $403530.0 in Q3 2023 and troughed at $15895.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Adial Pharmaceuticals | 26.99 Mn | 26.99 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 15,895.00 |
| Sep 30, 2023 | 403,530.00 |
| Jun 30, 2023 | 114,297.00 |
| Mar 31, 2023 | 341,134.00 |
| Dec 31, 2022 | 37,390.00 |
| Sep 30, 2022 | 85,587.00 |
| Jun 30, 2022 | 66,491.00 |